采用TLI-ATG预处理的行HLA错配无关供者移植的移植物抗宿主病风险低且抗肿瘤活性强
研究比较了斯坦福大学2001年12月至2015年5月连续接受TLI-ATG预处理后行8-9/10 HLA错配无关供者移植(MMUD,N=72)与10/10 HLA全合无关供者移植(MUD,N=193)的患者结局,中位年龄60岁,中位随访2年。两组在总生存、无病生存、非复发死亡、急性GVHD III-IV级及慢性GVHD方面均无显著差异;MMUD组复发有降低趋势,在淋系恶性肿瘤患者中差异显著。TLI-ATG预处理可能克服HLA错配供者传统上较差的结局,可能特别适合缺乏HLA全合供者的淋系恶性肿瘤患者。
要点
- MMUD组与MUD组5年总生存均为46%(P=0.86),无显著差异。
- MMUD组5年复发率45% vs MUD组60%(HR 0.71,P=0.094),呈降低趋势但未达统计学显著。
- 淋系恶性肿瘤患者中MMUD组5年复发率29% vs MUD组57%(HR 0.55,P=0.044),差异显著。
核心结论
- TLI-ATG预处理可能克服HLA错配供者传统上较差的结局,可能特别适合缺乏HLA全合供者的淋系恶性肿瘤患者。
- 达到完全供者嵌合与较低复发率强相关。
研究设计与样本
- 斯坦福大学2001年12月至2015年5月连续接受TLI-ATG预处理后行造血细胞移植患者的结局比较。
- MMUD组为8-9/10 HLA错配无关供者(N=72),MUD组为10/10 HLA全合无关供者(N=193)。
- 患者中位年龄60岁,中位随访2年,两队列淋系与髓系恶性肿瘤分布相似。
主要发现
- 5年总生存MMUD组46% vs MUD组46%(P=0.86),无显著差异。
- 5年无病生存MMUD组38% vs MUD组28%(P=0.25),无显著差异。
- 2年非复发死亡MMUD组17% vs MUD组12%(P=0.34),无显著差异。
- 第+100天急性GVHD III-IV级MMUD组6% vs MUD组3%(P=0.61),无显著差异。
- 5年慢性GVHD MMUD组39% vs MUD组35%(P=0.49),无显著差异。
关键数值与推荐
- MMUD组5年总生存46% vs MUD组46%(P=0.86)。
- MMUD组5年无病生存38% vs MUD组28%(P=0.25)。
- MMUD组2年非复发死亡17% vs MUD组12%(P=0.34)。
- MMUD组第+100天急性GVHD III-IV级6% vs MUD组3%(P=0.61)。
- MMUD组5年慢性GVHD 39% vs MUD组35%(P=0.49)。
临床怎么用
- TLI-ATG预处理可能克服HLA错配供者传统上较差的结局(作者认为)。
- TLI-ATG预处理可能特别适合缺乏HLA全合供者的淋系恶性肿瘤患者(作者认为)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Many patients lack a fully HLA-matched donor for hematopoietic cell transplantation (HCT), and HLA mismatch is typically associated with inferior outcomes. Total lymphoid irradiation and antithymocyte globulin (TLI-ATG) is a nonmyeloablative conditioning regimen that is protective against graft-versus-host disease (GVHD), and we hypothesized that the protective effect would extend beyond HLA-matched donors. We report outcomes for all consecutively transplanted patients at Stanford University from December 2001 through May 2015 who received TLI-ATG conditioning and HCTs from 8 to 9 out of 10 HLA-mismatched unrelated donors (MMUDs, N = 72) compared with 10 out of 10 HLA-matched unrelated donors (MUDs, N = 193). The median age of the patients was 60 years with a median follow-up of 2 years, and there was a similar distribution of lymphoid and myeloid malignancies in both cohorts. There were no significant differences between MMUD and MUD cohorts in overall survival (46% vs 46% at 5 years, P = .86), disease-free survival (38% vs 28% at 5 years, P = .25), nonrelapse mortality (17% vs 12% at 2 years, P = .34), acute GVHD grades III-IV (6% vs 3% at day +100, P = .61), or chronic GVHD (39% vs 35% at 5 years, P = .49). There was a trend toward less relapse in the MMUD cohort (45% vs 60% at 5 years, hazard ratio: 0.71, P = .094), which was significant for patients with lymphoid malignancies (29% vs 57% at 5 years, hazard ratio: 0.55, P = .044). Achieving full donor chimerism was strongly associated with lower relapse rates. TLI-ATG conditioning may overcome the traditionally poorer outcome associated with HLA-mismatched donors and may be particularly well suited for patients with lymphoid malignancies who lack HLA-matched donors.
引用
- Spinner MA, Fernández-Viña M, Creary LE, et al. HLA-mismatched unrelated donor transplantation using TLI-ATG conditioning has a low risk of GVHD and potent antitumor activity. Blood Adv. 2017. PMID: 29296777. doi:10.1182/bloodadvances.2017007716
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。